Medicalsystem Biotechnology Co., Ltd.
SZSE:300439.SZ
11.11 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,866.717 | 2,489.086 | 2,251.532 | 2,302.032 | 3,133.448 | 3,135.123 | 2,584.188 | 1,059.147 | 683.141 | 597.849 | 432.061 | 327.742 | 192.52 |
| Cost of Revenue
| 1,099.777 | 1,539.47 | 1,340.224 | 1,453.738 | 2,055.879 | 2,039.765 | 1,596.176 | 487.654 | 282.017 | 262.418 | 181.015 | 134.109 | 77.151 |
| Gross Profit
| 766.94 | 949.617 | 911.308 | 848.294 | 1,077.569 | 1,095.357 | 988.012 | 571.493 | 401.124 | 335.431 | 251.046 | 193.633 | 115.369 |
| Gross Profit Ratio
| 0.411 | 0.382 | 0.405 | 0.368 | 0.344 | 0.349 | 0.382 | 0.54 | 0.587 | 0.561 | 0.581 | 0.591 | 0.599 |
| Reseach & Development Expenses
| 137.943 | 171.784 | 150.684 | 135.481 | 128.26 | 109.64 | 185.137 | 115.715 | 39.931 | 24.191 | 17.504 | 13.295 | 0 |
| General & Administrative Expenses
| 66.069 | 64.352 | 53.7 | 63.089 | 76.767 | 75.645 | -18.008 | 1.51 | 36.919 | 25.803 | 18.595 | 13.68 | 24.822 |
| Selling & Marketing Expenses
| 262.519 | 300.364 | 297.954 | 272.768 | 364.526 | 315.854 | 262.517 | 152.142 | 107.398 | 84.601 | 59.101 | 36.341 | 20.978 |
| SG&A
| 374.732 | 364.717 | 351.654 | 335.856 | 441.293 | 391.499 | 244.509 | 153.652 | 144.317 | 110.404 | 77.696 | 50.022 | 45.799 |
| Other Expenses
| -1.509 | 100.283 | 113.06 | 108.395 | 130.987 | -1.304 | -25.742 | 4.85 | 15.374 | 1.967 | 4.059 | 8.177 | 1.526 |
| Operating Expenses
| 514.185 | 636.784 | 615.397 | 579.732 | 700.54 | 640.73 | 545.002 | 360.874 | 224.864 | 162.442 | 119.181 | 80.684 | 48.052 |
| Operating Income
| 252.755 | 322.017 | 294.196 | 461.427 | 410.713 | 341.712 | 345.654 | 203.301 | 176.153 | 164.784 | 125.069 | 106.338 | 66.149 |
| Operating Income Ratio
| 0.135 | 0.129 | 0.131 | 0.2 | 0.131 | 0.109 | 0.134 | 0.192 | 0.258 | 0.276 | 0.289 | 0.324 | 0.344 |
| Total Other Income Expenses Net
| 26.609 | -98.711 | -75.96 | -114.378 | -935.787 | -1.304 | 0.884 | 16.016 | 15.368 | 1.967 | 4.058 | 8.176 | 1.515 |
| Income Before Tax
| 279.364 | 223.306 | 218.236 | 347.049 | -525.075 | 340.408 | 346.538 | 219.317 | 191.522 | 166.751 | 129.127 | 114.514 | 67.664 |
| Income Before Tax Ratio
| 0.15 | 0.09 | 0.097 | 0.151 | -0.168 | 0.109 | 0.134 | 0.207 | 0.28 | 0.279 | 0.299 | 0.349 | 0.351 |
| Income Tax Expense
| 36.179 | 18.102 | 28.084 | 53.48 | 51.552 | 91.728 | 88.952 | 37.947 | 32.06 | 29.961 | 25.868 | 22.779 | 13.21 |
| Net Income
| 256.551 | 198.527 | 179.488 | 299.481 | -576.627 | 241.172 | 229.7 | 174.495 | 161.268 | 137.684 | 103.53 | 91.735 | 53.328 |
| Net Income Ratio
| 0.137 | 0.08 | 0.08 | 0.13 | -0.184 | 0.077 | 0.089 | 0.165 | 0.236 | 0.23 | 0.24 | 0.28 | 0.277 |
| EPS
| 0.67 | 0.52 | 0.48 | 0.87 | -1.68 | 0.71 | 0.66 | 0.52 | 0.52 | 0.54 | 0.41 | 0.36 | 0.21 |
| EPS Diluted
| 0.67 | 0.52 | 0.48 | 0.87 | -1.68 | 0.7 | 0.66 | 0.52 | 0.52 | 0.54 | 0.41 | 0.36 | 0.21 |
| EBITDA
| 437.493 | 513.689 | 489.017 | 634.946 | 572.197 | 615.603 | 541.854 | 307.356 | 239.339 | 205.765 | 156.853 | 133.418 | 73.703 |
| EBITDA Ratio
| 0.234 | 0.206 | 0.217 | 0.276 | 0.183 | 0.196 | 0.21 | 0.29 | 0.35 | 0.344 | 0.363 | 0.407 | 0.383 |